Early research (Phase 1)Study completedNCT03821233What this trial is testingA Dose Finding Study of ZW49 in Patients With HER2-Positive CancersWho this might be right forHER2-expressing Cancers Zymeworks BC Inc. 112
Testing effectiveness (Phase 2)Active Not RecruitingNCT04430738What this trial is testingTucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersWho this might be right forColorectal CarcinomaGastric AdenocarcinomaGEJ Adenocarcinoma+3 more Seagen, a wholly owned subsidiary of Pfizer 40
Testing effectiveness (Phase 2)Study completedNCT01037790What this trial is testingPhase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerWho this might be right forAdult Solid TumorAdenocarcinoma of the ColonAdenocarcinoma of the Rectum+36 more Abramson Cancer Center at Penn Medicine 304
Testing effectiveness (Phase 2)WithdrawnNCT05356897What this trial is testingTucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWho this might be right forMetastatic Colon AdenocarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Rectal Adenocarcinoma+3 more Academic and Community Cancer Research United
Early research (Phase 1)Looking for participantsNCT03740256What this trial is testingBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsWho this might be right forBladder CancerHead and Neck Squamous Cell CarcinomaCancer of the Salivary Gland+7 more Baylor College of Medicine 45
Early research (Phase 1)Study completedNCT03841110What this trial is testingFT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsLymphomaGastric Cancer+15 more Fate Therapeutics 37
Testing effectiveness (Phase 2)Looking for participantsNCT05672524What this trial is testingTucatinib and Trastuzumab in People With Rectal CancerWho this might be right forAdenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma+2 more Memorial Sloan Kettering Cancer Center 37
Testing effectiveness (Phase 2)Looking for participantsNCT07407465What this trial is testingUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.Who this might be right forColorectal CancerColorectal AdenocarcinomaRectal Adenocarcinoma+4 more Gruppo Oncologico del Nord-Ovest 42
Not applicableEnded earlyNCT04106167What this trial is testingLong-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyWho this might be right forAdvanced Solid TumorLymphomaGastric Cancer+15 more Fate Therapeutics 20
Not applicableLooking for participantsNCT07124000What this trial is testingDESTINY-PANTUMOUR04Who this might be right forAdenocarcinoma (NOS)Anal CancerBladder Cancer+24 more AstraZeneca 100
Early research (Phase 1)Looking for participantsNCT04704661What this trial is testingTesting the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialWho this might be right forAdvanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802876What this trial is testingEfficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsWho this might be right forMSI-H Colorectal CancerMelanomaAnal Carcinoma+28 more SOLTI Breast Cancer Research Group 184
Not applicableApproved For MarketingNCT04100694What this trial is testingEarly Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorWho this might be right forNRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more Merus B.V.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07243938What this trial is testingPhase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)Who this might be right forLocally Advanced Rectal Cancer (LARC)Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaMetastatic Colorectal Cancer (mCRC)+1 more Tao Zhang 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07405476What this trial is testingZanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent TreatmentWho this might be right forColon CarcinomaColorectal CarcinomaRectal Carcinoma+9 more Emory University 38
Early research (Phase 1)Study completedNCT01576666What this trial is testingPhase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsWho this might be right forDose EscalationSafetyPreliminary Efficacy+9 more Novartis Pharmaceuticals 120
Early research (Phase 1)Looking for participantsNCT07318805What this trial is testingLearn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsWho this might be right forAdvanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Colorectal Cancer+2 more Pfizer 260
Early research (Phase 1)Study completedNCT02900664What this trial is testingPDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)Who this might be right forColorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma Novartis Pharmaceuticals 283
Early research (Phase 1)Study completedNCT03319459What this trial is testingFATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsWho this might be right forHER2 Positive Gastric CancerColorectal CancerHead and Neck Squamous Cell Carcinoma+8 more Fate Therapeutics 44
Testing effectiveness (Phase 2)Study completedNCT03602079What this trial is testingStudy of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneWho this might be right forHER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more Klus Pharma Inc. 49